Pharmacokinetics of l-749,345, a long-acting carbapenem antibiotic, in primates

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1743-1748

  Sundelof, J G ^a   Hajdu, R ^a   Gill, C J ^a   Thompson, R ^a   Rosen, H ^a   Kropp, H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOACYLASE; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; ERTAPENEM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BACILLUS SUBTILIS; BIOASSAY; CHIMPANZEE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG URINE LEVEL; ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

EID: 0030744630     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1743     Document Type: Article

References (21)

1. Craig, W. A. 1996. Antimicrobial resistance issues of the future. Diagn. Microbiol. Infect. Dis. 25:213-217.
2. Curry, S. H. 1980. Drug disposition and pharmacokinetics, 3rd ed., p. 187-194. Blackwell Scientific Publications Ltd., Oxford, United Kingdom.
3. Dorso, K., J. Kohler, L. L. Silver, and H. Kropp. 1996. Bactericidal effect of L-749,345 on Staphylococcus aureus and Serratia marcescens in the presence and absence of human serum, abstr. F123, p. 121. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Drusano, G. L. 1986. An overview of the pharmacology of imipenem/cilastatin. J. Antimicrob. Chemother. 18(Suppl. E):79-92.
5. Gerckens, L. S., B. A. Pelak, R. Thompson, H. Rosen, and H. Kropp. 1996. Pharmacokinetic evaluation of L-749,345 (ZD-4433), a long-acting parenteral carbapenem in rodents, abstr. F127, p. 122. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society tor Microbiology, Washington, D.C.
6. Gill, C. J., J. J. Jackson, J. G. Sundelof, H. Rosen, and H. Kropp. 1996. In vivo activity of a novel long-acting carbapenem antibiotic, L-749,345, in mouse models of localized and systemic bacterial infections, abstr. F125, p. 121. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Gold, H. S., and R. C. Moellering. 1996. Antimicrobial-drug resistance. N. Engl. J. Med. 335:1445-1453.
8. Holzman, M. S. 1991. Antimicrobial formulary management: a consultant's perspective. Pharmacotherapy 11(Suppl. 1, part 2):14S-18S.
9. Jacoby, G., and P. Han. 1996. Comparative in vitro activity of carbapenem L-749,345 ('345) and other antimicrobials against multiresistant Gram negative clinical pathogens, abstr. F120, p. 120. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Kath, G., W. McKeel, and J. Sundelof. 1993. Bacterial zone measurement apparatus. Meas. Sci. Technol. 4:231-233.
11. Kohler, J., K. Dorso, B. A. Pelak, L. S. Gerckens, G. G. Hammond, L. L. Silver, and H. Kropp. 1996. In vitro activity of the potent, broad spectrum carbapenem L-749,3454 against BDS βL-producing Escherichia coli and Klebsiella pneumoniae, abstr. F122, p. 121. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Kropp, H., J. G. Sundelof, R. Hajdu, and K. M. Kahan. 1982. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I. Antimicrob. Agents Chemother. 22:62-70.
13. Majumdar, A., K. Birk, R. A. Blum, A. M. Cairns, J. Conroy, C. M. Mendel, D. Musson, and J. D. Rogers. 1996. Pharmacokinetics of L-749,345, a carbapenem antibiotic, in healthy male and female volunteers, abstr. F130, p. 122. In Abstracts of the 36th Interscienee Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
14. Norrby, S. R., B. Björnegård, F. Ferber, and K. H. Jones. 1983. Pharmacokinetics of imipenem in healthy volunteers. J. Antimicrob. Chemother. 12 (Suppl. D):109-124.
15. Patel, I. H., S. Chen, M. Parsonnet, M. R. Hackman, M. A. Brooks, J. Konikoff, and S. A. Kaplan. 1981. Pharmacokinetics of ceftriaxone in humans. Antimicrob. Agents Chemother. 20:634-641.
16. Pelak, L. S. Gerckens, P. M. Scott, C. Gill, C. Pacholok, L. Lynch, K. Dorso, J. Kohler, D. Shungu, and H. Kropp. 1996. Antibacterial profile of L-749,345 (ZD-4433), a new potent 1-β-methyl carbapenem, abstr. F119, p. 120. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
17. Roark, M. K., and W. E. Reed, Jr. 1995. Econotherapeutics. Diagn. Microbiol. Infect. Dis. 22:209-217.
18. Scott, P. M., C. J. Gill, D. L. Shungu, and H. Kropp. 1996. Comparative in vitro activity of L-749,345 against respiratory tract bacterial pathogens, abstr. F121, p. 121. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
19. 18a. Sundelof, J. G., C. J. Gill, R. Thompson, H. Rosen, and H. Kropp. 1996. Disposition of an extended half-life carbapenem in rhesus monkeys, chimpanzees and humans, abstr. F128, p. 122. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
20. Sundelof, J. G., R. Thompson, K. M. White, M. W. Sasor, L. Cama, and H. Kropp. 1996. Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 40:795-798.
21. Synergy Software. 1994. KaleidaGraph, version 3.0.5. Synergy Software, Reading, Pa.